CHemical OptImization of Cerebral Embolectomy 2 (CHOICE 2).

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 440 participants.

Also called NCT05797792

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 440 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05797792
  • EudraCT 2023-504262-32
Other papers using this trial's data
  • Adjunctive Intra-Arterial Alteplase After Successful Thrombectomy for Acute Ischemic Stroke: The CHOICE-2 Randomized Clinical Trial JAMA, 2026-06-02 DOI, PubMed 42096239, PMC13154035 Not in the PMC Open Access subset.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Spain (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05797792. Randomized; single masking; primary purpose treatment. Start 2023-11-18 (actual); primary completion 2025-08-26 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
CHemical OptImization of Cerebral Embolectomy 2 (CHOICE 2).
Acronym
CHOICE2
Condition
Stroke, Acute Ischemic
Condition
Stroke, Acute
Intervention (Drug)
Intraarterial alteplase
Lead sponsor
Hospital Clinic of Barcelona (class: other)

Record details

Record id
cardio:ct-nct05797792
Content hash
c87223e014596e5db4591438ebf2f5388ac8f831fdcca7656a574f29f62558b4